# Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

> **NCT05124210** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Sotrovimab

## Key facts

- **NCT ID:** NCT05124210
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-16
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants
- **Last updated:** 2024-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05124210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05124210, "Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05124210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*